Management of refractory ischemic priapism: current perspectives

Marco Capece 1
Arianna Gillo 2
Andrea Cocci 3
Giulio Garaffa 1
Massimiliano Timpano 4
Marco Falcone 4

1 The Institute of Urology, University College of London Hospital (UCLH), London, UK; 2 Department of Urology, ‘Umberto Parini’ Hospital, Aosta, 3 Department of Urology, Careggi Hospital, Firenze, 4 Department of Urology, University of Turin, Città della Salute e della Scienza, Turin, Italy

Objectives: The aim of the present manuscript is to review the current literature on priapism, focusing on the state-of-the-art knowledge of both the diagnosis and the treatment of the refractory ischemic priapism (IP).

Methods: Pubmed and EMBASE search engines were used to search for words “priapism”, “refractory priapism”, “penile prosthesis”, “diagnosis priapism”, “priapism treatment”, “penile fibrosis”, “priapism therapy”. All the studies were carefully examined by the authors and then included in the review.

Results: First-line treatment involves ejaculation, physical exercise and cold shower followed by corporal blood aspiration and injection of α-adrenoceptor agonists. Subsequently, a distal or proximal shunt may be considered. If none of the treatment is effective or the priapism episode lasts >48 hours penile prosthesis implantation could be the only option to solve the priapism and treat the ongoing erectile dysfunction.

Conclusion: The management of IP is to achieve detumescence of persistent penile erection and to preserve erectile function after resolution of the priapic episode. On the other hand, penile fibrosis and following shortening should be prevented. Early penile prosthesis implantation in patients with refractory IP is able to solve both the priapic episode and prevent the otherwise certain penile shortening. Penile prosthesis implantation is the actual gold standard of care in cases of refractory IP.

Keywords: priapism, ischemic priapism, penile fibrosis, penile prosthesis, shunt

Objectives
The aim of the present manuscript is to review the current literature on priapism, focusing on the state-of-the-art knowledge of both the diagnosis and the treatment of the refractory ischemic priapism (IP).

Acquisition of evidence
A review has been conducted using Pubmed and EMBASE as search engines. The Medline search using the words “priapism” as a mesh term with “refractory”, “penile prosthesis”, “diagnosis”, “treatment”, “fibrosis”, “therapy”, was carried out in February 2017. All the publications were examined by all the authors and disagreements on the conclusions were resolved by discussion among them.

Synthesis of evidence
Definition and classification
Priapism is a prolonged erection that persists longer than 4 hours, irrespective of any sexual stimulation and beyond the reaching of an orgasm. The condition can be
classified into three main categories: non-ischemic priapism (NIP – also known as “arterial” or “high-flow”), the much more frightening IP–(also known as “veno-occlusive” or “low-flow”) and finally, a third rare variant, the stuttering priapism (“recurrent” or “intermittent”) characterized by repetitive and painful episodes of IP.1,2

IP is the most common type of priapism, accounting for up to 95% of all priapic events.3 The pathological mechanism underlying this phenomenon is an obstruction of the penile venous outflow, which leads to a stasis of hypoxic blood within the corpus cavernosum akin to a proper compartment syndrome leading to hypoxia, hypercapnia, acidosis and glucopenia.4,5

There are many underlying causes of IP; however the most common are hematological diseases, drugs, intracorporeal injection of vasoactive drugs, neurological disease and malignancy.3,6–9

It is a rare condition with overall incidence of 1.5 cases per 100,000 person-years; however it is an important urologic condition as it could be a symptom hiding a hemoglobinopathy such as sickle cell disease, thalassemia or hematological malignancies, which cause an obliteration of the small emissary veins in the subtunical space and lead to the ischemic condition as it could be a symptom hiding a hemoglobinopathy such as sickle cell disease, thalassemia or hematological malignancies, which cause an obliteration of the small emissary veins in the subtunical space and lead to the ischemic episodes.3 According to the recent European Association of Urology guidelines, a variety of agents can be considered for intracavernosal injection: phenylephrine, etilephrine and adrenaline.1 Phenylephrine should be diluted in normal saline to a concentration of 100–500 µg/mL and 1 mL given every 3–5 minutes, up to a maximum dosage of 1 mg, while adrenaline can be diluted to 1/100,000 mg/mL and 2 mL given for a maximum of five times throughout a period of 20 minutes.1

Moreover, the presence of acidosis, glucopenia and hypoxia contribute to the cavernosal smooth muscle dysfunction.5

If left untreated, unless the rare occurrence of a malignant infiltration of the corpora occurs, the degree of tumescence tends to subside spontaneously within and the necrotic cavernosal tissue progresses into an extended fibrosis, resulting in severe erectile dysfunction refractory to any medical treatment and eventually in a shortened penis.13

**Diagnosis**

The diagnosis of IP is based on a detailed past medical history, genital clinical examination (as the pain is a classical finding in IP), radiological imaging and blood gas analysis. We underline the necessity of a urine toxicology examination, a hematological screening and an abdominal/pelvis scan, before asserting the idiopathic cause of the IP.

Color Doppler Ultrasound (DUS) of the penis certainly plays a role in assessing the presence of any flow in the cavernosal arteries to differentiate IP from NIP. In the case of IP, DUS shows a peculiar pattern of absent or reduced flow within the cavernosal arteries, while in NIP, the DUS of the penis often shows a normal or increased flow and irregular flow from the artery to the cavernosal body at the site of injury, suggestive of an arterial-lacunar fistula. However, the most reliable investigation to distinguish between IP and NIP is corporal blood gas analysis, which will typically show ischemic, venous blood with pO2 <30 mmHg and pCO2 >60 mmHg, and pH <7.25 in cases of low-flow priapism.1,2

**First-line treatments**

Once the diagnosis of IP has been confirmed, the initial management involves ejaculation, physical exercise and cold shower to stimulate the noradrenergic system, leading to smooth muscle contraction and eventually inducement of detumescence.1,2 If a conservative approach fails, corporal blood irrigation followed by an instillation of α-agonists directly into the corpus cavernosum is considered as the most valuable option. The drainage of the corporal ischemic blood has been evaluated as being effective in >36% of IP episodes.3 According to the recent European Association of Urology guidelines, a variety of agents can be considered for intracavernosal injection: phenylephrine, etilephrine and adrenaline.1 Phenylephrine should be diluted in normal saline to a concentration of 100–500 µg/mL and 1 mL given every 3–5 minutes, up to a maximum dosage of 1 mg, while adrenaline can be diluted to 1/100,000 mg/mL and 2 mL given for a maximum of five times throughout a period of 20 minutes.1
Corporal blood aspiration and intracorporeal injection of α-adrenergic agents are recommended if the priapic event lasts >24–36 hours, although these patients are very unlikely to respond due to smooth muscle necrosis.

**Surgical interventions**

If corporal blood aspiration and injections of α-adrenergic agonists fail, the second-line treatment consists of a penile shunt surgery. Distal shunts should be attempted before proximal shunts, because they are easier to perform and have low incidence of complications.

The Winter shunt is the most common percutaneous procedure. With this intervention, a fistula between the corpus spongiosum and the corpora cavernosa is created. The shunt can be created also with an open procedure. Al Ghorab’s shunt, for example, consists of an open excision of the circular cone segment of the distal tunica albuginea and subsequent skin closure. In any case, the choice of a specific approach is left to the surgeon’s experience.

In the event of an IP lasting >36 hours, shunt surgery is unlikely to be effective. In these types of cases, early penile prosthesis (PP) implantation can be considered. The shunt surgery is even less effective if the duration of priapism is >48 hours. In these cases, the success rate is extremely low in contrast to the incidence of severe erectile dysfunction (ED) in which the success rate proved to be extremely high.15–19

**Early penile prosthesis implantation**

When none of the above treatments are effective or after 48 hours of duration of the IP, an early insertion of PP is an option. In this group of patients, indeed, the natural course of the disturb brings to a severe ED associated with a significant shortening of the shaft secondary to a diffuse corporal fibrosis, located particularly in the distal corpora. An early implantation before the development of a dense fibrosis has been demonstrated to give more satisfactory results, preserving the length of the shaft as well as reducing the risk related to a difficult penile implantation in a fibrotic penis. In fact, it is no doubt true that recent reports have underlined that immediate PP implantation in these patients can resolve the painful erection, guarantee adequate long-term rigidity for sexual penetration and prevent the otherwise inevitable penile shortening.13,20,21–31

A potential overtreatment in patients with no evidence of necrosis in the cavernosal smooth muscle is one of the risks associated with this approach. Therefore, correct timing of the surgery is essential. Preoperative penile magnetic resonance imaging (MRI) and cavernosal smooth muscle biopsies during the shunt procedure, or frozen sections during the implantation surgery are mandatory to confirm the presence of necrosis and to assist the surgeon in the eventual decision to proceed with the insertion of an implant.20 MRI of the penis has been demonstrated to reach a sensitivity of nearly 100% when used to detect the presence of necrosis of the cavernosal smooth muscle.32 Thus, the potential risk of overtreatment is easily overcome by performing either a penile MRI or a cavernosal biopsy during the shunt procedure.

**Surgical technique**

An early penile prosthesis implantation is usually approached by a single transverse penoscrotal incision, away from the oedematous penile skin or previous incisions. Intravenous (IV) antibiotic prophylaxis is mandatory, and we suggested an IV administration for 3 days postoperatively, which should then be switched to oral for another 4 days. Both corpora are carefully isolated and longitudinally incised. A biopsy of the endocavernosal tissue is performed and when possible a frozen section examination is requested. The corpora are usually easily dilated with Hegar’s or Brook’s dilators, as the fibrosis has not yet occurred. Extensive corporal washout with antibiotic (rifampicin and gentamicin) is performed. Finally, the PP is inserted. The risk of postoperative hematoma formation can be minimized with the use of a close circuit drain and with the application of a compressive dressing (mummy-wrap).20

**Early versus delayed penile prosthesis implantation**

If the IP episode is treated conservatively, the use of a vacuum pump associated with pde 5 inhibitors can be proposed as an option to recover the erectile function. However, if necrosis of the corporal smooth muscle has already occurred, rehabilitation will be ineffective and the patient will develop a refractory ED with fibrosis and shortening of the penis.13,20

The dense fibrosis involving the penis after refractory IP damages the distal part of the corpora, while the proximal corpora are usually spared. On the other hand, refractory IP patients not responding to aspirations, pharmacological treatments or shunt surgery are destined to a PP implantation if they want to continue an active sexual life. The accurate timing of the setting of irreversible changes in the corpora cavernosa is still unknown and it represents the main open issue in the management of patients with a delayed IP presentation. The most common complication of early implant is the higher risk of infection (6%–7%) compared with virgin implantation. Clearly, this is related to the previous aspiration
or percutaneous shunt, which creates a link between the skin and the corpora cavernosa, increasing the risk of introducing bacteria in a sterile environment. Nevertheless, the edema of the cavernosal tissues reduces the penetration of the antibiotic. The longer the procedure is delayed, the greater the risk corporal fibrosis will be found. The exact timing of the formation of a penile fibrosis after a IP episode is still under debate, even if some recent evidences suggested that a straightforward implantation is possible 4 weeks after the IP episode.4,13,20,26,29

The second open issue is the choice of the type of implant (malleable vs inflatable). Most authors chose to insert a malleable penile prosthesis as a first-choice implant because the compartment syndrome secondary to IP tends to be a fibrotic process of the tissue that surrounds the cylinders of the implant. The malleable implant, which is semi-rigid by definition, protects itself from any form of contracture or penile deformity. On the other hand, a risk of distal erosion sharply higher than with inflatable implants (up to 6%) must be considered in patients who have undergone percutaneous distal shunt.13–24,33–35 Inflatable PP can be considered as an option, but the implant must be cycled daily after 1 week to prevent the risks aforementioned.36

Inserting a PP in patients with severe corporal fibrosis represents a real challenge, with high risk of complications such as urethral injuries, distal or lateral perforation, cylinders crossover and infection. In these cases, the use of a blunt dilation by Hegar’s or Brook’s dilators is usually not adequate to dilate the corpora, and Rossello or Uramix cavernotomes are often needed to excise fibrotic tissue to make space for accommodating the cylinders (the concept of “cavernosal drilling”). Adopting this technique, the infection rate is 6.3%, and the revision rate at 1 year is 13%.36–38

Moreover, accessory incision, most commonly a subcoronal one associated with a distal corporotomy, is often required to create a cavernosal channel under direct vision. Alternatively, in an attempt to minimize the dissection, the transverse penoscrotal incision can be extended distally along the rafe down to the coronal sulcus in “T”-shaped fashion to obtain a wider corpora on the ventral aspect.36 As previously stated, the surgery in these selected cases can be extremely challenging, complication rates can be as high as 65%, with up to 30% of patients experiencing infection of the device, and an overall prosthesis survival of only 50% at 1 year.36 Nevertheless, whichever technique is used, once the shortening of the penis has happened there is no way to restore it, although some authors advocate the implantation of downsized inflatable devices that would act as tissue expanders and to upsize them after 6–12 months.39

Conclusions
Nowadays, the goal of the management of IP is to achieve detumescence of persistent penile erection and to preserve erectile function after resolution of the priapic episode. Cavernosal tissue damage in IP is time related, even if the specific timing of irreversible damage is still unknown. Conservative measures and aspiration, with or without intracorporeal instillation of α-adrenergic agonists, are usually successful in the early stages, but become useless after 48–72 hours when the necrosis of the smooth muscle has occurred. Percutaneous shunt surgery remains debatable, as the lack of response to aspiration and instillation of α-adrenergic agonists indicates that irreversible changes in the cavernosal smooth muscle are likely to have already occurred. Therefore, shunt surgery may relieve the painful erection but will not prevent the formation of fibrosis and the consequent erectile dysfunction, which is not the actual aim of the treatment.

In this scenario, early penile prosthesis implantation in patients with refractory IP is able to solve the priapic episode and prevent the otherwise penile shortening. Regarding the erectile function, when the fibrosis occurs, the chances of recovering are inconsistent, and the penile implant could be the only solution to this issue.

Although complication rates after immediate insertion of PP in refractory IP are higher than in virgin cases, they are still lower compared to delayed PP implantation after severe corporal fibrosis. Clearly, if one knew that smooth muscle necrosis had already occurred at the time of the IP episode, then any attempt to perform shunt surgery should be avoided at the first instance to reduce the complication rate after the implant.

In conclusion, PP implantation is the actual gold standard of care in cases of refractory IP, and if performed within a few weeks from the priapic episode avoids penile shortening, surgical complication and patient dissatisfaction.

Disclosure
The authors report no conflicts of interest in this work.

References